Mycosis Fungoides Treatment Market Report 2021-2028 | Size, Share, Growth, Trends, Covid-19 Impact, Statistics, Competitive Landscape, Regional Analysis, Forecast
Key Companies Covered in the Oncology Drugs MarketResearch Report Are: Astellas Pharma, Inc., Pfizer Inc., Bayer AG, Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc, Abbott, Mylan N.V, Other key market players
/EIN News/ -- Pune, India, July 23, 2021 (GLOBE NEWSWIRE) -- The global mycosis fungoides treatment market is set to gain impetus from the increasing recommendation of various treatment options by physicians. It depends on the severity of the disease. This information is given by Fortune Business Insights™ in an upcoming report, titled, “Mycosis Fungoides Treatment Market Size, Share & Industry Analysis, By Drug Type (Topical Steroids, Mechlorethamine, Interferons, Others), By Treatment (Photodynamic Therapy, Radiation Therapy, Chemotherapy, Others), By End User (Hospitals, Speciality Clinics, Others) and Regional Forecast, 2019-2026.” The report further states that patients who arein thelast stage of the disease are often advised to use monoclonal antibodies.
KEY DEVELOPMENTS:
- June 2020: Kyowa Kirin, a Japan-based drug maker launched Poteligeo in Europe. It would be able to treat patients with Sézary syndrome, mycosis fungoides, and rare cancers.
- June 2020:The U.S. FDA lifted the hold of Innate Pharma’s Phase 2 clinical trial of TELLOMAK. The company is currently studying the safety and efficacy of this lacutamab in patients living with advanced T-cell lymphomas.
Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/mycosis-fungoides-treatment-market-103137
Drivers & Restraints-
Increasing Patient Pool Suffering from Weak Immune Systems will Aid Growth
The increasing prevalence of lymphoma cancer is one of the vital factors for the mycosis fungoides treatment market growth. Besides, the rising patient poolsuffering from weak immune systems, as well as an increasing aging population worldwide would propel growth. The National Institute of Health (NIH) declared that the cases of mycosis fungoides are 1 in per 100,000 to 350,000 people globally.
Moreover, the surging demand for monoclonal antibodiesin terms of first-line therapy is expected to boost growth in the coming years. Coupled with this, the increasing advancements in technology associated with chemotherapy is set to affect growth positively. However, the treatment has multiple side-effects, which in turn, may hamper growth.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/mycosis-fungoides-treatment-market-103137
Regional Analysis-
Rising Expenditure on Healthcare Infrastructure to Provide Europe Second Leading Position
Geographically, North America is likely to dominate in the forthcoming years by procuring the highest mycosis fungoides treatment market share. This growth is attributable to the presence of several reputed companies, such as Pfizer and Astellas Pharma in the region.The Cutaneous Lymphoma Foundation mentioned thatevery year, in the U.S. approximately 3000 new cases of cutaneous T cell lymphoma (CTCL) are reported.
Europe, on the other hand, is set to remain in the second position in the near future. The rising number of new product launches, increasing awareness regarding healthcare, and surging expenditure in healthcare expenditure are projected to bolster growth in this region. Asia Pacific is expected to showcase a considerablegrowth fueled by the increasing partnerships between research centres and biopharmaceutical companies.
Ask for Customization:
Competitive Landscape-
Key Players Focus on Unveiling New Treatment Options to Intensify Competition
The market for mycosis fungoidestreatment is highly fragmented with the presence of several companies worldwide. Each of them is striving to introduce innovative mycosis fungoides treatment options by conducting extensive research activities.Below are two latest industry developments:
Fortune Business Insights™ lists out the names of all the renowned mycosis fungoides treatment providers operating in the global market. They are as follows:
- Astellas Pharma, Inc.
- Bayer AG
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Abbott
- Mylan N.V
- Other key market players
Speak to our Research Analysts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/mycosis-fungoides-treatment-market-103137
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
